Coadministration of glucagon-like peptide-1 during glucagon infusion in humans results in increased energy expenditure and amelioration of hyperglycemia

Diabetes

Volumn 62, Issue 4, 2013, Pages 1131-1138

  Tan, Tricia M ^a   Field, Benjamin C T ^a   McCullough, Katherine A ^a   Troke, Rachel C ^a   Chambers, Edward S ^a   Salem, Victoria ^a   Maffe, Juan Gonzalez ^b   Baynes, Kevin C R ^a   De Silva, Akila ^a   Viardot, Alexander ^a   Alsafi, Ali ^a   Frost, Gary S ^a   Ghatei, Mohammad A ^a   Bloom, Stephen R ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GHRELIN; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CALORIMETRY; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; INSULIN BLOOD LEVEL; MALE; OBESITY; OXIDATION; PRIORITY JOURNAL; PROTEIN DEPLETION; RANDOMIZED CONTROLLED TRIAL; RESTING ENERGY EXPENDITURE;

ADULT; CALORIMETRY, INDIRECT; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; ENERGY METABOLISM; FEMALE; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPERGLYCEMIA; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED;

EID: 84875409178     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db12-0797     Document Type: Article

References (39)

1. Cryer PE. Minireview: glucagon in the pathogenesis of hypoglycemia and hyperglycemia in diabetes. Endocrinology 2012;153:1039-1048
2. Jones BJ, Tan T, Bloom SR. Minireview: glucagon in stress and energy homeostasis. Endocrinology 2012;153:1049-1054
3. Drucker DJ. The role of gut hormones in glucose homeostasis. J Clin Invest 2007;117:24-32
4. Bataille D, Gespach C, Tatemoto K, et al. Bioactive enteroglucagon (oxyntomodulin): present knowledge on its chemical structure and its biological activities. Peptides 1981;2(Suppl. 2):41-44
5. Dakin CL, Gunn I, Small CJ, et al. Oxyntomodulin inhibits food intake in the rat. Endocrinology 2001;142:4244-4250
6. Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 1998;101:515-520
7. Astrup A, Rössner S, Van Gaal L, et al.; NN8022-1807 Study Group. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 2009;374:1606-1616
8. Flint A, Raben A, Rehfeld JF, Holst JJ, Astrup A. The effect of glucagonlike peptide-1 on energy expenditure and substrate metabolism in humans. Int J Obes Relat Metab Disord 2000;24:288-298
9. Schulman JL, Carleton JL, Whitney G, Whitehorn JC. Effect of glucagon on food intake and body weight in man. J Appl Physiol 1957;11:419-421
10. Nair KS. Hyperglucagonemia increases resting metabolic rate in man during insulin deficiency. J Clin Endocrinol Metab 1987;64:896-901
11. Cohen MA, Ellis SM, Le Roux CW, et al. Oxyntomodulin suppresses appetite and reduces food intake in humans. J Clin Endocrinol Metab 2003; 88:4696-4701
12. Wynne K, Park AJ, Small CJ, et al. Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial. Int J Obes (Lond) 2006;30:1729-1736
13. Wynne K, Park AJ, Small CJ, et al. Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial. Diabetes 2005;54:2390-2395
14. Maida A, Lovshin JA, Baggio LL, Drucker DJ. The glucagon-like peptide-1 receptor agonist oxyntomodulin enhances beta-cell function but does not inhibit gastric emptying in mice. Endocrinology 2008;149:5670-5678
15. Day JW, Ottaway N, Patterson JT, et al. A new glucagon and GLP-1 coagonist eliminates obesity in rodents. Nat Chem Biol 2009;5:749-757
16. Pocai A, Carrington PE, Adams JR, et al. Glucagon-like peptide 1/glucagon receptor dual agonism reverses obesity in mice. Diabetes 2009;58:2258-2266
17. Pelkman CL, Chow M, Heinbach RA, Rolls BJ. Short-term effects of a progestational contraceptive drug on food intake, resting energy expenditure, and body weight in young women. Am J Clin Nutr 2001;73:19-26
18. Weir JB. New methods for calculating metabolic rate with special reference to protein metabolism. J Physiol 1949;109:1-9
19. Frayn KN. Calculation of substrate oxidation rates in vivo from gaseous exchange. J Appl Physiol 1983;55:628-634
20. Kraegen EW, Lazarus L, Meler H, Campbell L, Chia YO. Carrier solutions for low-level intravenous insulin infusion. BMJ 1975;3:464-466
21. Kreymann B, Williams G, Ghatei MA, Bloom SR. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 1987;2:1300-1304
22. Ghatei MA, Uttenthal LO, Bryant MG, Christofides ND, Moody AJ, Bloom SR. Molecular forms of glucagon-like immunoreactivity in porcine intestine and pancreas. Endocrinology 1983;112:917-923
23. Wren AM, Small CJ, Ward HL, et al. The novel hypothalamic peptide ghrelin stimulates food intake and growth hormone secretion. Endocrinology 2000;141:4325-4328
24. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999;402:656-660
25. Geary N, Kissileff HR, Pi-Sunyer FX, Hinton V. Individual, but not simultaneous, glucagon and cholecystokinin infusions inhibit feeding in men. Am J Physiol 1992;262:R975-R980
26. Arafat MA, Otto B, Rochlitz H, et al. Glucagon inhibits ghrelin secretion in humans. Eur J Endocrinol 2005;153:397-402
27. Hagemann D, Holst JJ, Gethmann A, Banasch M, Schmidt WE, Meier JJ. Glucagon-like peptide 1 (GLP-1) suppresses ghrelin levels in humans via increased insulin secretion. Regul Pept 2007;143:64-68
28. Billington CJ, Briggs JE, Link JG, Levine AS. Glucagon in physiological concentrations stimulates brown fat thermogenesis in vivo. Am J Physiol 1991;261:R501-R507
29. Miyoshi H, Shulman GI, Peters EJ, Wolfe MH, Elahi D, Wolfe RR. Hormonal control of substrate cycling in humans. J Clin Invest 1988;81:1545-1555
30. Ali S, Drucker DJ. Benefits and limitations of reducing glucagon action for the treatment of type 2 diabetes. Am J Physiol Endocrinol Metab 2009;296: E415-E421
31. Holst JJ, Knop FK, Vilsbøll T, Krarup T, Madsbad S. Loss of incretin effect is a specific, important, and early characteristic of type 2 diabetes. Diabetes Care 2011;34(Suppl. 2):S251-S257
32. Garber AJ. Incretin effects on b-cell function, replication, and mass: the human perspective. Diabetes Care 2011;34(Suppl 2):S258-S263
33. Bertin E, Arner P, Bolinder J, Hagström-Toft E. Action of glucagon and glucagon-like peptide-1-(7-36) amide on lipolysis in human subcutaneous adipose tissue and skeletal muscle in vivo. J Clin Endocrinol Metab 2001; 86:1229-1234
34. Samols E, Marri G, Marks V. Interrelationship of glucagon, insulin and glucose. The insulinogenic effect of glucagon. Diabetes 1966;15: 855-866
35. Ranganath L, Schaper F, Gama R, Morgan L. Does glucagon have a lipolytic effect? Clin Endocrinol (Oxf) 2001;54:125-126
36. Arafat AM, Perschel FH, Otto B, et al. Glucagon suppression of ghrelin secretion is exerted at hypothalamus-pituitary level. J Clin Endocrinol Metab 2006;91:3528-3533
37. Altman DG. Practical Statistics for Medical Research. London, Chapman and Hall, 1991
38. Bland M. An Introduction to Medical Statistics. Oxford, U.K., Oxford University Press, 1995
39. Goldstein H, Browne W, Rasbash J. Partitioning variation in multilevel models. Underst Stat 2002;1:223-231